Form 4: Travere Therapeutics CCO Gifts Shares Under 10b5-1 Plan

Travere Therapeutics' Chief Commercial Officer, Peter Heerma, made a charitable gift of 891 shares of common stock under a pre-arranged 10b5-1 plan.

Summary

• Peter Heerma, Chief Commercial Officer of Travere Therapeutics, Inc. (TVTX), disposed of 891 shares of common stock.
• The transaction occurred on September 23, 2025, and was reported as a charitable gift (Transaction Code G).
• The gift was made to a donor-advised fund pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c).
• The shares were disposed of at a price of $0, consistent with a gift.
• Following this transaction, Peter Heerma beneficially owns 127,324 shares of Travere Therapeutics common stock.

Sentiment

Score: 5

Explanation: A routine insider transaction (charitable gift) with no direct positive or negative implications for company performance or valuation.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is a routine insider transaction by a company officer and does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Minimal direct impact on shareholders as it is a small, pre-planned charitable gift by an officer, not indicative of operational changes or financial distress.

Key Dates

Recommendation

This Form 4 filing reports a routine charitable gift of a small number of shares by a Chief Commercial Officer, executed under a pre-arranged 10b5-1 plan. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It is a standard disclosure of an insider's personal stock transaction.

Keywords

Travere Therapeutics, TVTX, Peter Heerma, Chief Commercial Officer, Form 4, Insider Transaction, Charitable Gift, Stock Disposition, Rule 10b5-1